C4 Therapeutics, Inc. (CCCC) Tops Q1 EPS by 9c

C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q1 EPS of ($0.37), $0.09 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $7.24 million versus the consensus estimate of $4.74 million.

For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• Qualcomm (QCOM) Is Said To Near Deal For Ai Chip Startup Modular - Bloomberg
• A.O. Smith executive chairman to retire, CEO to assume chairman role